Janssen R&D’s Immunology Unit Grounded In Translational Thinking
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J finished pulling together its disparate R&D efforts under the Janssen name in December, with a distinctive translational thread running through the entire soup-to-nuts operation. The immunology unit showcases the firm’s success with this method – the understanding of a psoriasis mechanism gained in the clinic looped back to inform research on several next generation therapies and a very broad Remicade label.
You may also be interested in...
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results
Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.
How Biologics Are Powering J&J’s Resurgent Drug Business: An Interview with Jay Siegel
After well-publicized problems in Johnson & Johnson’s devices and consumer health divisions, in the words of a recent Deutsche Bank research note, “It’s pharmaceuticals’ time to shine.” Indeed, the diversified health care company expects to file 11 new drugs and over 31 line extensions by 2015. Though growth is now expected from J&J’s pharma business, less well understood is the role of biologics, both marketed and near to market, in driving that expansion and J&J’s increased focus on specialty products.